A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Abstract Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-01964-1 |